Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06564844
Title	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)
Acronym	TROPION-Lung12
Recruitment	Not yet recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	lung adenocarcinoma
Therapies	Tegafur-gimeracil-oteracil Potassium Etoposide AZD2936 + Datopotamab deruxtecan Carboplatin AZD2936 Vinorelbine Pemetrexed Disodium Cisplatin
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL